Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.

Background: Chronic obstructive pulmonary disease (COPD) represents an illness with significant healthcare and societal impacts. Fixed combinations of long-acting beta-agonists (LABA) and inhaled corticosteroids have been used for COPD treatment as the standard of care for many years. A daily dose of indacaterol and glycopyrronium (IND/GLY) at 110/50 µg has recently been gaining attention due to its improved efficacy and tolerability versus the standard of care.

[Chronic obstructive pulmonary disease--acute bacterial exacerbations].

COPD (Chronic obstructive pulmonary disease) belongs to leading causes of morbidity and mortality worldwide and results in substantial and everincreasing medical, social and economic burden. The same applies to the Czech Republic as well. To combat the disease the Global Initiative for Obstructive Lung Disease (GOLD) has been founded in collaboration with the World Health Organization (WHO).